Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives FDA considers adding a dozen peptides to its bulk drug compounding list RAPS FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List When will the FDA reclassify BPC 157 to Category 1 Octagon AI